Slight Improvement on Bayer’s Situation with Yaz and Yasmin Litigation
A German drug manufacturer has been hit hard with thousands of lawsuits for its defective birth control product, but the situation is improving as the number of complaints taper off.
Bayer has been the focus of more than 13,000 lawsuits filed by users of oral contraceptive products Yaz and Yasmin, which contains drospirenone, a synthetic hormone, in combination with ethinyl estradiol. It has also been used “off-label” to prevent acne and some forms of severe premenstrual syndrome.
Numerous studies indicate that drospirenone increases the risk for developing blood clots by as much as 74%, which in turn can induce strokes, deep vein thrombosis or pulmonary embolism. This was confirmed by a study conducted by the Food and Drug Administration in 2011. Use of the drug declined sharply when the findings were published even as the number of lawsuits increased.
Recently, however, it seems that the influx of new cases is finally slowing down, although the company is still busy coping with existing litigation. This is good news for the beleaguered pharmaceutical company. On average, Bayer paid out $207,000 per case in settlements, for a total of more than $1.4 Billion.